Isabelle Desmoulins
Centre Georges François Leclerc(FR)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Cancer Genomics and Diagnostics
Most-Cited Works
- → Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial(2020)1,743 cited
- → A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)(2016)278 cited
- → Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer(2018)167 cited
- → Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort(2021)127 cited
- → Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study(2020)105 cited
- → Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication(2021)85 cited
- → HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy(2014)80 cited
- → Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer(2021)71 cited
- → Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer(2015)68 cited
- → Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer(2013)68 cited